Review article: Follow-up of coeliac disease.

Authors:
Tye-Din JA.

Journal:
Aliment Pharmacol Ther

Publication Year: 2022

DOI:
10.1111/apt.16847

PMCID:
PMC9542881

PMID:
35815829

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Aliment Pharmacol Ther

Abbreviation: Aliment Pharmacol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic…
Wijarnpreecha K; Li F; Lundin SK and 5 more (2023) - Transparency Score: 3/6
Longer time to recovery from acute kidney injury is associated with major adverse kidney events in …
Patidar KR; Naved MA; Kabir S and 9 more (2023) - Transparency Score: 3/6
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for s…
Hermann RP; Rockey DC; Suzuki A and 2 more (2022) - Transparency Score: 3/6
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disea…
Meade S; Patel KV; Luber RP and 17 more (2022) - Transparency Score: 4/6
Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogas…
Visaggi P; Ghisa M; Del Corso G and 11 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of personal interests : JAT‐D has privately or via his institute been a consultant or advisory board member for ImmusanT Inc, Codexis, Chugai Pharmaceuticals, Genentech, IM Therapeutics, Mozart Therapeutics, Janssen, Anokion and Roche and has received research funding from Chugai Pharmaceuticals, Codexis, ImmusanT Inc., Novoviah Pharmaceuticals and Tillots Pharmaceuticals. He is an inventor on patents relating to the use of gluten peptides in coeliac disease diagnosis and treatment."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025